No-Reflow Phenomenon: Maintaining Vascular Integrity
- 1 September 2011
- journal article
- review article
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 16 (3-4) , 244-250
Abstract
The no-reflow phenomenon relates to the inability to reperfuse regions of the myocardium after ischemia, despite removal of the large epicardial coronary artery occlusion. The mechanism involves microvascular obstruction. In experimental studies, using markers for flow (thioflavin S, carbon black, microspheres), perfusion defects associated with no-reflow demonstrated ultrastructural evidence of localized endothelial swelling and blebs that appeared to obstruct flow. In humans no-reflow is more complicated due to the microemboli of atherosclerotic debris and thrombi generated by percutaneous coronary intervention. The no-reflow zone expands during the first few hours of reperfusion suggesting an element of reperfusion injury. In animal models, extensive no-reflow was associated with worse infarct expansion. The phenomenon of no-reflow following reperfusion therapy for myocardial infarction in humans has been demonstrated by magnetic resonance imaging, echo contrast agents, thallium, technecium-99m-labeled albumin microspheres, Thrombolysis In Myocardial Infarction (TIMI) scores, and myocardial blush grade. Patients exhibiting no-reflow following reperfusion therapy for myocardial infarction have greater left ventricular dilation and remodeling, more congestive heart failure, shock, and reduced survival. Certain vasodilators (adenosine, nitroprusside, nicorandil, and calcium blockers) are used acutely in the catheterization laboratory and appear to improve no-reflow, but systematic studies on therapy for no-reflow are needed. There is now clinical evidence that no-reflow is a strong predictor of long-term mortality that is independent of and beyond that provided by infarct size. Identifying and treating no-reflow may have important benefits including enhancing delivery of nutrients and cells required for healing and reducing infarct expansion and ventricular remodeling, which ultimately may reduce congestive heart failure and mortality.Keywords
This publication has 26 references indexed in Scilit:
- The Antianginal Agent, Ranolazine, Reduces Myocardial Infarct Size but Does Not Alter Anatomic No-Reflow or Regional Myocardial Blood Flow in Ischemia/Reperfusion in the RabbitJournal of Cardiovascular Pharmacology and Therapeutics, 2008
- No-Reflow Phenomenon Persists Long-Term After Ischemia/Reperfusion in the Rat and Predicts Infarct ExpansionCirculation, 2003
- Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarctionCardiovascular Research, 2003
- Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbitAmerican Journal of Physiology-Heart and Circulatory Physiology, 2002
- The “no-reflow” phenomenon: basic science and clinical correlatesHeart, 2002
- Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow.Circulation, 1989
- Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi?Circulation, 1989
- The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion.Circulation, 1984
- The “No-Reflow” Phenomenon after Temporary Coronary Occlusion in the DogJournal of Clinical Investigation, 1974
- Blood Supply of the Myocardium after Temporary Coronary OcclusionCirculation Research, 1966